481 related articles for article (PubMed ID: 23290213)
21. Neurocognitive profiles in MSUD school-age patients.
Bouchereau J; Leduc-Leballeur J; Pichard S; Imbard A; Benoist JF; Abi Warde MT; Arnoux JB; Barbier V; Brassier A; Broué P; Cano A; Chabrol B; Damon G; Gay C; Guillain I; Habarou F; Lamireau D; Ottolenghi C; Paermentier L; Sabourdy F; Touati G; Ogier de Baulny H; de Lonlay P; Schiff M
J Inherit Metab Dis; 2017 May; 40(3):377-383. PubMed ID: 28324240
[TBL] [Abstract][Full Text] [Related]
22. Combined nutritional support and continuous extracorporeal removal therapy in the severe acute phase of maple syrup urine disease.
Jouvet P; Jugie M; Rabier D; Desgrès J; Hubert P; Saudubray JM; Man NK
Intensive Care Med; 2001 Nov; 27(11):1798-806. PubMed ID: 11810125
[TBL] [Abstract][Full Text] [Related]
23. An improved ultra performance liquid chromatography-tandem mass spectrometry method for the determination of alloisoleucine and branched chain amino acids in dried blood samples.
Alodaib A; Carpenter K; Wiley V; Sim K; Christodoulou J; Wilcken B
Ann Clin Biochem; 2011 Sep; 48(Pt 5):468-70. PubMed ID: 21775576
[TBL] [Abstract][Full Text] [Related]
24. [3 patients with maple syrup urine disease].
Merinero B; del Valle JA; García MJ; García Miguel MJ; Barrio MI; García Hortelano J; Morales E; González F; García Aparicio J; Sáez Pérez E
An Esp Pediatr; 1983 Nov; 19(5):393-400. PubMed ID: 6660657
[TBL] [Abstract][Full Text] [Related]
25. Second-tier test for quantification of alloisoleucine and branched-chain amino acids in dried blood spots to improve newborn screening for maple syrup urine disease (MSUD).
Oglesbee D; Sanders KA; Lacey JM; Magera MJ; Casetta B; Strauss KA; Tortorelli S; Rinaldo P; Matern D
Clin Chem; 2008 Mar; 54(3):542-9. PubMed ID: 18178665
[TBL] [Abstract][Full Text] [Related]
26. Intermittent branched chain ketonuria (variant of maple syrup urine disease).
Irwin WC; Martel SB; Goluboff N
Clin Biochem; 1971 Jun; 4(2):52-8. PubMed ID: 5128296
[No Abstract] [Full Text] [Related]
27. [Maple syrup urine disease and cystathioninemia].
Simma B; Sperl W; Berger H
Padiatr Padol; 1989; 24(1):69-75. PubMed ID: 2497426
[TBL] [Abstract][Full Text] [Related]
28. Impact of longitudinal plasma leucine levels on the intellectual outcome in patients with classic MSUD.
Hoffmann B; Helbling C; Schadewaldt P; Wendel U
Pediatr Res; 2006 Jan; 59(1):17-20. PubMed ID: 16326996
[TBL] [Abstract][Full Text] [Related]
29. [Advances in the diagnosis and treatment of maple syrup urine disease: experience in Galicia (Spain)].
Couce Pico ML; Castiñeiras Ramos DE; Bóveda Fontán MD; Iglesias Rodríguez AJ; Cocho de Juan JA; Fraga Bermúdez JM
An Pediatr (Barc); 2007 Oct; 67(4):337-43. PubMed ID: 17949643
[TBL] [Abstract][Full Text] [Related]
30. Variant maple syrup urine disease in mother and daughter.
Zaleski LA; Dancis J; Cox RP; Hutzler J; Zaleski WA; Hill A
Can Med Assoc J; 1973 Aug; 109(4):299-300 passim. PubMed ID: 4730202
[TBL] [Abstract][Full Text] [Related]
31. Definition of the mutation responsible for maple syrup urine disease in Poll Shorthorns and genotyping Poll Shorthorns and Poll Herefords for maple syrup urine disease alleles.
Dennis JA; Healy PJ
Res Vet Sci; 1999 Aug; 67(1):1-6. PubMed ID: 10425233
[TBL] [Abstract][Full Text] [Related]
32. Urinary biomarkers of oxidative damage in Maple syrup urine disease: the L-carnitine role.
Guerreiro G; Mescka CP; Sitta A; Donida B; Marchetti D; Hammerschmidt T; Faverzani J; Coelho Dde M; Wajner M; Dutra-Filho CS; Vargas CR
Int J Dev Neurosci; 2015 May; 42():10-4. PubMed ID: 25680940
[TBL] [Abstract][Full Text] [Related]
33. Branched-chain organic acidurias.
Ogier de Baulny H; Saudubray JM
Semin Neonatol; 2002 Feb; 7(1):65-74. PubMed ID: 12069539
[TBL] [Abstract][Full Text] [Related]
34. [Acute encephalopathy due to late-onset maple syrup urine disease in a school boy].
Qu SQ; Yang LC; Luan Z; Du K; Yang H
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Mar; 14(3):161-4. PubMed ID: 22433398
[TBL] [Abstract][Full Text] [Related]
35. Biochemical studies on a variant of branched chain ketoaciduria in a 19-year-old female.
Fischer MH; Gerritsen T
Pediatrics; 1971 Nov; 48(5):795-801. PubMed ID: 5125877
[No Abstract] [Full Text] [Related]
36. Pathophysiology of maple syrup urine disease: Focus on the neurotoxic role of the accumulated branched-chain amino acids and branched-chain α-keto acids.
Amaral AU; Wajner M
Neurochem Int; 2022 Jul; 157():105360. PubMed ID: 35577033
[TBL] [Abstract][Full Text] [Related]
37. Maple syrup urine disease: analysis of branched chain ketoacid decarboxylation in cultured fibroblasts.
Wendel U; Wentrup H; Rüdiger HW
Pediatr Res; 1975 Sep; 9(9):709-17. PubMed ID: 1202420
[TBL] [Abstract][Full Text] [Related]
38. Newborn screening for maple syrup urine disease (branched-chain ketoaciduria).
Naylor EW; Guthrie R
Pediatrics; 1978 Feb; 61(2):262-6. PubMed ID: 416414
[TBL] [Abstract][Full Text] [Related]
39. Clinical consequences of disorders in the intermediate metabolism of branched chain amino acids (valine, leucine and isoleucine).
Mogoş T; Cheţa CP; Mincu IT
Rom J Intern Med; 1994; 32(1):57-61. PubMed ID: 8081313
[TBL] [Abstract][Full Text] [Related]
40. Maple syrup urine disease (branched-chain keto-aciduria) variant type manifesting as hyperkinetic behaviour and mental retardation. Report of two cases.
Kalyanaraman K; Chamukuttan S; Arjundas G; Gajanan N; Ramamurthi B
J Neurol Sci; 1972 Feb; 15(2):209-17. PubMed ID: 5010106
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
